Atovaquone Oral Suspension Recalled for Cohnella Bacteria Contamination
Bionpharma Inc. is recalling Atovaquone Oral Suspension (750 mg/5 mL) nationwide due to Cohnella bacteria contamination. The recall affects 1,980 bottles.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I drug recall for bacterial contamination of a non-sterile pharmaceutical product. FDA Class I classification mandates a minimum severity score of 4. No illnesses or injuries have been reported.
Plain-English summary
Bionpharma Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL in 210 mL bottles due to contamination with Cohnella bacteria. The affected product has lot number 2310083 with an expiration date of 09/30/2025.
Atovaquone is a non-sterile prescription oral suspension used as an antimalarial and antiprotozoal medication. The contamination poses a potential risk to consumers using this product.
The recalled product consists of 1,980 bottles that were distributed nationwide in the United States. Consumers who have obtained this medication should contact their healthcare provider or pharmacy for guidance.
The recalled product
- Product
- ATOVAQUONE (ATOVAQUONE)
- Brand
- ATOVAQUONE
- Manufacturer
- Bionpharma Inc.
- Category
- Drug — Oral Suspension
- Hazard
- bacterial-contamination
- cohnella
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 2310083
- Exp. 09/30/2025
UPCs (1)
- 0369452252871
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATOVAQUONE
- SevereAtovaquone Oral Suspension Recalled for Bacillus cereus Contamination
FDA (Drugs) · 2023-05-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27